Human herpesvirus 6 (HHV-6) infection and the HHV-6-specific lymphocyte proliferation response were studied longitudinally in 24 patients in the first 3 months after allogeneic stem cell transplantation (allo-SCT). HHV-6 DNAemia was analyzed by a nested PCR method, and the HHV-6-specific lymphocyte proliferation responses were evaluated with a standard lymphocyte proliferation assay. All patients who responded to HHV-6 GS (variant A) antigen also responded to HHV-6 Z29 (variant B) antigen, and a response to HHV-6 Z29 antigen was detected more often than to HHV-6 GS antigen after allo-SCT (P = 0.048). HHV-6 DNA was detected in more patients after than before transplantation (P = 0.01) and in more patients with acute GVHD grades II-IV than those without (P = 0.009). An HHV-6-specific proliferative response was more often detected in patients without, than in those with persistent HHV-6 infection (three consecutively positive PBL samples; P Ͻ 0.001). Patients with persistent HHV-6 infection had lower lymphocyte counts from the 8th week after transplantation than those without (P = 0.03). No HHV-6-specific proliferation responses were detected in the three patients who developed HHV-6 disease. HHV-6 infection was associated with persistent lymphocytopenia and might thereby inhibit immune function.
endothelial cells, astrocytes and glial cell lines have also been documented. 1 HHV-6 infection of peripheral blood cells in vitro results in reduced interleukin-2 (IL-2) synthesis and decreased cellular proliferation induced by mitogens or antigens. 4, 5 Furthermore, HHV-6 induces IL-1␤, IL-10 and tumor necrosis factor alpha production in peripheral blood mononuclear cell cultures. 6, 7 HHV-6 infection in vivo may have similar effects on the immune system. Allogeneic stem cell transplantation (allo-SCT) is characterized by an ablative conditioning therapy, followed by establishment of hematopoiesis of donor origin and restoration of the immune function in the recipient. HHV-6 is closely related to cytomegalovirus (CMV), 8 and like CMV, HHV-6 infection is common in the period when the immune function is profoundly suppressed after allo-SCT. 9 ,10 HHV-6 infection after allo-SCT has been associated with febrile episodes, skin rash, bone marrow suppression, interstitial pneumonitis, and fatal encephalitis. 10 However, most HHV-6 infections seem to be asymptomatic.
The aim of this prospective study was to analyze the HHV-6-specific lymphocyte proliferation response in allo-SCT recipients. The effects of HHV-6 infection on reconstitution of peripheral blood lymphocytes and leukocytes were also analyzed.
Materials and methods

Patient population
From October 1995 to January 1998, 26 patients who underwent allo-SCT were included in the study. Two patients were not included in the analyses; one due to relapse at the time of allo-SCT and the other due to early death. The study was approved by the ethical committee at the Huddinge University Hospital. Patient characteristics are given in Table 1 . Conditioning therapy consisted of either cyclophosphamide and total body irradiation or cyclophosphamide and oral busulphan. All patients with unrelated donors also received either anti-thymocyte globulin or anti-T cell antibody (OKT-3) before transplantation. Prophylaxis of acute graft-versus-host disease (GVHD) was with the combination of cyclosporin A and methotrexate. No T cell depletion was performed. Patients with acute GVHD grades I or II were treated with prednisolone (2 mg/kg/day) either intravenously or orally for 1 week. The dose of prednisolone was then tapered.
Blood samples
Peripheral blood was collected 1 or 2 weeks before transplantation, weekly from the 3rd to the 6th week, and every 2nd week thereafter until the 12th week after transplantation. Heparin tubes were used for lymphocyte proliferation studies and EDTA tubes for detection of HHV-6 and CMV DNA. During the study period, 26 healthy adults working at the Huddinge University Hospital or the Swedish Institute for Infectious Disease Control were used as controls. Twenty persons in the control group were female and six were male; the average age was 39 years (range 24-60).
Lymphocyte proliferation assay
Lymphocyte proliferation assay was performed as previously reported. 11 Briefly, peripheral blood mononuclear cells (PBMC) were isolated by Ficoll-Hypaque (Pharmacia Biotech, Uppsala, Sweden) and resuspended in culture medium consisting of RPMI 1640 supplemented with glutamine, penicillin, streptomycin, 10 −5 mol 2-mercaptoethanol (Life Technologies, Paisley, UK) and 10% human AB+, CMV seronegative serum. Human serum of the same batch was used throughout this study. PBMC were added into 96-well flat-bottom plates (1.5 × 10 5 /well; Nunclon Delta, Nunc, Aarhus, Denmark). All assays were performed in triplicate to quintruplicate depending on the amount of available PBMC. Cell lysates predominantly containing viral nucleocapsid antigens from HHV-6 GS or HHV-6 Z29 strain were prepared according to a previously published method, 12 and used at previously determined optimal dilutions. 11 The control antigens were prepared in the same way from uninfected HSB-2 or Molt-3 cells. Proliferation was measured by 
Serology
HHV-6 serology was determined by indirect immunofluorescence using HSB-2 cells infected with the GS strain as the antigen, and CMV serology was determined by an ELISA method. 13 HHV-6 and CMV serology of the healthy individuals were analyzed at the Swedish Institute for Infectious Disease Control, and CMV serology for the patients and donors was performed at the Department of Clinical Virology, Huddinge University Hospital.
14 Thirteen patients had plasma samples available for HHV-6 serology determination before transplantation.
PCR methods
HHV-6 DNA in peripheral blood leukocytes (PBL) collected as buffy coats was detected by a PCR method. 9 Sensitivity of the PCR for HHV-6 DNA has been evaluated to be 20-30 genomes for both the GS and Z 29 strains. PBL from 25 of the 26 healthy controls were available for analysis. CMV DNA in PBL from the patients was detected by a PCR method at the Department of Clinical Virology, Huddinge University Hospital, and the detection limit of this method was 10 genomes. 14 
Definitions
Delayed granulocyte engraftment was defined as an absolute neutrophil count of 0.5 × 10 9 /l, occurring later than day 25 after transplantation. Acute GVHD was defined according to Thomas et al. 15 HHV-6 DNA in PBL detectable by PCR is very common after allo-SCT. Therefore, a definition of persistent HHV-6 infection was used in this study to increase the likelihood of HHV-6 DNA detection to be of clinical importance. This definition required detection of HHV-6 DNA in three consecutive PBL specimens. HHV-6 disease (encephalitis and hepatitis) was diagnosed when the patients had symptoms from the infected organ, presence of HHV-6 DNA in the organ, and no other likely pathogens. The diagnosis of HHV-6 encephalitis was accepted if there was a positive PCR finding in cerebrospinal fluid together with central nervous system symptoms, and no other possible pathogens. 16 
Statistics
Results were analyzed by Fisher's exact test (two-tailed). Numbers of lymphocyte counts and leukocyte counts were analyzed by the Mann-Whitney U test.
Results
Lymphocyte proliferation responses in healthy individuals
All healthy individuals were HHV-6 seropositive. Six of 26 (23%) had a lymphocyte proliferation response to the HHV-6 GS antigen (variant A), while 14 of 26 (54%) had a response to the HHV-6 Z29 (variant B) antigen (P = 0.04). All the 26 healthy adults responded to PHA.
Lymphocyte proliferation responses in allo-SCT recipients
Thirteen patients were available for analysis before allo-SCT and all were HHV-6 seropositive. Five of the 13 (39%) patients responded to the HHV-6 GS antigen while seven of 13 (54%) patients responded to the HHV-6 Z29 antigen. After allo-SCT, five of 24 (21%) patients responded to the HHV-6 GS antigen while seven of 24 (29%) patients responded to the HHV-6 Z29 antigen. Lymphocyte proliferation responses induced by PHA were demonstrated in all patients before, and repeatedly demonstrated in 23 of 24 (96%) patients after allo-SCT.
All individuals who responded to the HHV-6 GS antigen also responded to the Z29 antigen. The c.p.m. of proliferation responses to the Z29 antigen were higher than those to the GS antigens in the majority of tests of both healthy individuals and patients before transplantation (data not shown). Moreover, lymphocyte proliferation responses to the HHV-6 GS antigen were not detected as often as to the HHV-6 Z 29 antigen after transplantation (9/139 tests vs 20/139 tests, P = 0.048). Therefore, only the responses to the HHV-6 Z 29 antigen were used in the following analyses.
The kinetics of recovery of antigen-specific lymphocyte proliferation responses after transplantation are shown in Figure 1 . The responses to HHV-6 Z29 were inhibited immediately after allo-SCT, and recovered from the 10th week after allo-SCT.
Five of 12 (42%) patients with HLA-identical donors responded to the HHV-6 Z29 antigen compared with two of 12 (17%) patients with unrelated donors (P = NS). One out of seven patients with acute GVHD grades II-IV responded to the HHV-6 Z29 antigen compared with six of 17 patients without acute GVHD (P = NS).
Viral DNA identification
HHV-6 DNA was detected in six of 15 (40%) patients before and 20 of 24 (83%) patients after allo-SCT respectively (P = 0.01). Six out of seven patients with acute GVHD II-IV had persistent HHV-6 infection after allo-SCT, compared with four of 17 patients without acute GVHD (P = 0.009). Two of eight bone marrow transplant (BMT) recipients and five of 16 peripheral blood stem cell transplant (PBSCT) recipients had persistent HHV-6 infection until the end of the study or death (P = NS). Persistent HHV-6 infection was detected in all the three patients who later developed HHV-6 diseases (two cases with encephalitis and one case with hepatitis). Acute GVHD grade II was diagnosed in one of the patients with encephalitis and in the patient with hepatitis. However, liver biopsy did not reveal any sign of acute GVHD in the patient with hepatitis. Instead, HHV-6 DNA was detected in the liver biopsy and no other possible pathogens could be identified. Both patients received prednisolone treatment, and the patient with hepatitis also received anti-thymocyte globulin in the last 3 days before death.
HHV-6 infection and lymphocyte proliferation responses to HHV-6 Z29
A lymphocyte proliferation response to the HHV-6 Z 29 antigen was detected in five of 20 (25%) patients with HHV-6 DNAemia compared with two of four (50%) patients without detectable HHV-6 DNA in PBL during the study period (P = NS). Patients with one or no HHV-6 DNA-positive PBL sample tended to show a HHV-6-specific lymphocyte proliferation response more frequently than those with two consecutively HHV-6 DNA-positive PBL specimens (P = 0.08), or those with persistent HHV-6 infection (P Ͻ 0.001; Figure 2 sistent HHV-6 infection responded to HHV-6 Z29 antigen, compared with six of 14 (43%) patients who had intermittent or no HHV-6 DNAemia (P = 0.17; 1/54 vs 19/84 tests, P Ͻ 0.001). No influence of HHV-6 infection on responses to PHA was observed. A positive lymphocyte proliferation response to HHV-6 was never detected in any of the three patients with HHV-6 disease.
Reconstitution of peripheral blood leukocytes and lymphocytes
Leukocyte and lymphocyte counts were routinely analyzed at weekly intervals after transplantation. All patients showed normal time to neutrophil engraftment. However, patients with persistent HHV-6 infection had lower absolute leukocyte counts at 5-6 weeks after transplantation (data not shown). There was no significant difference in lymphocyte counts between the two groups of patients in the 1st month after transplantation. However, patients with persistent HHV-6 infection had significantly lower lymphocyte counts from the 8th week after allo-SCT than those with intermittent or no HHV-6 DNAemia ( Figure 3 , P = 0.03). Twenty-one patients survived 12 weeks after transplantation, seven out of eight patients with persistent HHV-6 infection had not reached normal lymphocyte counts compared with three of 13 patients with intermittent or no HHV-6 DNAemia (P = 0.008). Five patients with acute GVHD grades II-IV survived more than 12 weeks after allo-SCT, and four of them responded to prednisolone treatment. The fifth patient in addition received anti-thymocyte globulin with limited effect. Four out of five patients with acute GVHD grades II-IV had low lymphocyte counts (Ͻ1 × 10 9 /l), compared with six of 16 patients without acute GVHD (P = NS). The only patient with acute GVHD grade II and a normal lymphocyte count 12 weeks after allo-SCT did not have detectable HHV-6 DNA in PBL. There was no correlation between CMV serology, CMV DNAemia and low lymphocyte counts (data not shown).
Discussion
Lymphocyte proliferation response to HHV-6 was analyzed in a group of healthy individuals, and patients before and after allo-SCT. A proliferation response was detected more frequently to HHV-6 Z29 (variant B) antigen than to HHV-6 GS (variant A) antigen in healthy adults. 11 Similarly, a response to the Z29 antigen tended to be more often detected than to the GS antigen in patients both before and after allo-SCT. It is probable that these results reflect that infection with HHV-6 variant B is more common than with variant A. It has been reported that lymphocyte proliferation responses induced by viral antigens are highly specific, and viral nucleocapsid antigens are better inducers of lymphocyte proliferation than membrane antigens. 17 The cell lysates used in this study have previously been shown to function well in the lymphocyte proliferation assay. 11 We found that patients with persistent HHV-6 infection were less likely to respond to HHV-6 antigen stimulations compared with patients without or with intermittent HHV-6 DNAemia, which suggests that HHV-6 infection may inhibit the immune response either generally or selectively. The hypothesis of immune suppression by HHV-6 is also supported by the finding that the ability to respond to HHV-6 antigen improved from the 10th week, at the same time as the HHV-6 DNA load decreased. It is noteworthy that HHV-6 infection had no effect on the T cell response to PHA, indicating that HHV-6 does not induce a general unresponsiveness of lymphocytes. However, studies on antigen-specific immune responses are needed to clarify this issue, since more cells can respond to PHA than to specific antigens. It has been reported that PBSCT leads to an earlier recovery of antigen-specific immune recovery than BMT. 18 However, PBSCT did not reduce the rates of CMV infection and CMV disease. 19 Similarly, PBSCT recipients do not seem to clear HHV-6 DNAemia more rapidly than BMT recipients, as shown in this study.
Meyers et al 20 reported that the immune responses to CMV are suppressed immediately after allogeneic bone marrow transplantation and recover only after an active CMV infection. Furthermore, patients who did not develop a CMV-specific proliferation response were at increased risk for severe CMV disease. 20, 21 Similarly, HHV-6-specific proliferation response was also profoundly depressed immediately after transplantation. However, half of the patients who did not have detectable HHV-6 DNA in PBL after allo-SCT developed a lymphocyte proliferation response to HHV-6 Z29 antigen. Recovery of a lymphoproliferation response after allo-SCT demands the presence of antigen-primed T lymphocytes. It is possible that the responsive cells were of donor origin. 22 There may also have been a transient HHV-6 infection in the first 3 weeks when PBL were not available, or HHV-6 antigens might have been expressed by cells other than peripheral blood leukocytes.
Acute GVHD can lead to imbalances of T lymphocytes and reduce CMV-specific proliferation responses. 23 Accordingly, there was a tendency for HHV-6-specific lymphocyte proliferation responses to be less frequently detected in patients with acute GVHD grades II-IV in this study, and six of seven patients with acute GVHD grades II-IV had persistent HHV-6 infection. However, we also found that persistent HHV-6 infection was related to decreased lymphocyte proliferation responses even in the patients without acute GVHD (data not shown). Another finding in this study was that patients with persistent HHV-6 DNAemia had significantly lower numbers of lymphocytes than did other patients from the 8th week after allo-SCT. HHV-6 can productively infect human T lymphocytes, influence interleukin production, inhibit T cell proliferation and induce T cell apoptosis. [4] [5] [6] [7] 24 Furthermore, the only patient with acute GVHD grade II and normal lymphocyte counts at 12th week after allo-SCT had no HHV-6 DNAemia. Thus, it is possible that HHV-6 may contribute to lymphocytopenia and the lack of HHV-6-specific lymphocyte proliferation responses of these patients. Human herpesvirus 7 (HHV-7) is a virus closely related to HHV-6, which can also induce CD4 + T cell death. 25 However, HHV-7 DNA was detected less frequently in PBL after than before transplantation, as shown previously, 9 and HHV-7 DNAemia neither influenced the number of lymphocyte counts nor HHV-6-specific lymphocyte proliferation responses (data not shown). Similarly, no relationship was found between lymphocytopenia and the presence of either acute GVHD grades II-IV or persistent CMV infection (data not shown). Acute GVHD does not affect the rate of lymphocyte reconstitution in the early period after allo-SCT. 26 In addition, most of our patients with acute GVHD were only treated with prednisolone, suggesting that the effect of acute GVHD on lymphocytopenia as noticed in this group of patients is limited.
The lymphocyte proliferation method mainly detects activation of CD4 + T lymphocytes. 27 CD4 + lymphocytes play a central role in the immune response by controlling the activity of B lymphocytes, cytotoxic T lymphocytes, and macrophages. Einsele et al 28 reported that CMV infection was correlated to severe acute GVHD after allo-SCT. However, it was lymphocytopenia (predominantly less CD4 + T lymphocytes) rather than severe acute GVHD that was related to the development of CMV diseases. 28 Dockrell et al 29 have reported that seroconversion to HHV-6 after liver transplantation can be a marker of CMV disease. Likewise, active CMV infection was related to HHV-6 isolation after allogeneic BMT. 30 Delayed reconstitution of CD4 + T cells has been reported to be correlated with an increased risk of life-threatening CMV infection. 31 Thus, our data provide the first in vivo evidence that HHV-6 infection might inhibit the immune system thus contributing to infections by other pathogens such as CMV. Studies of the effect of HHV-6 infection on CMV-specific immune response may help to further clarify this issue.
Both in vitro and in vivo studies have shown that HHV-6 is sensitive to ganciclovir and foscarnet. 9, 32, 33 From this point of view, the observation that patients who developed HHV-6-associated diseases or those with lymphocytopenia had persistent HHV-6 DNAemia is of importance, since it may serve as a marker for initiating and monitoring of antiviral therapy.
In summary, the ability to respond to HHV-6 Z29 antigen was profoundly inhibited after allo-SCT. Persistent HHV-6 DNAemia was associated with absence of a lymphocyte proliferation response and lymphocytopenia, which may contribute to CMV and other infectious complications after allo-SCT.
